Article
Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer.
Pharmacogenetics and genomics - 1 Jun 2011
Vargens Daniela D, Neves Ronaldo R S, Bulzico Daniel A, Ojopi Elida B, Meirelles Ricardo M R, Pessoa Cencita N, Prado Carolina M, Gonçalves Pedro A, Leal Vera L G, Suarez-Kurtz Guilherme
Abstract excerpt
There is a considerable interindividual variation in L-thyroxine [3,5,3',5'-tetraiodo-l-thyronine (T4)] dose required for thyrotropin (thyroid-stimulating hormone) suppression in patients with differentiated thyroid cancer. To investigate whether uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)-mediated T4 glucuronidation in liver affects T4 dose, we genotyped 101 patients for the common UGT1A1-53(TA)n...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.